杨海燕etal 神经胶质瘤多组学研究进展 4. Yung WK. From GWAS risk foci to glioma JC, Zheng J, Poon WS. Genetic alterations molecular subclass. Neuro-oncology 2013, in pediatric high-grade astrocytomas 15(5):513514 Human Pathol1999,30(11):1284-1290 5. Rood BR, MacDonald TJ. Pediatric high- 14. Xiao Wz, Han DH, Wang f, Wang YQ, Zhu grade glioma: molecular genetic clues for YH, Wu YF, Liu NT, Sun JY. Relationships innovative therapeutic approaches. J Neuro- between Pten gene mutations and onco2005,75(3):267-272. prognosis in glioma: a meta-analysis Tumour 6. Isolan gr. ribas filho jm. isolan pm Bio2014,35(7):6687-6693 Giovanini A, Malafaia o, Dini Ll, Kummer 15. Han F, Hu R, Yang H, Liu J, Sui J, Xiang A, Jr, Negrao AW. Astrocytic neoplasms X, Wang F, Chu L, Song S PtEn gene and correlation with mutate p53 and Ki- mutations correlate to poor prognosis 67 proteins. Arquivos de Neuro-psiquiatria in glioma patients: a meta-analysis 2005,63(4):997-1004 Oncotargets Ther 2016, 9: 3485-3492 7. Wang YY, Zhang T, Li sW, Qian TY, Fan X, 16. Preusser M, Haberler C, Hainfellner JA Peng XX, Ma J, Wang L, Jiang T Mapping Malignant glioma: neuropathology and p53 mutations in low-grade glioma: a neurobiology. Wiener Medizinis che voXel-based neuroimaging analysis. Am J Wochenschrift 2006, 156(11-12): 332-337. Neuroradiol2015,36(1):70-76. 17. Hulleman E. Helin K molecular mechanism 8. Panciani pp giordana mt gallone s in gliomagenesis. Adv Cancer Res 2005 Muratori A, Rotunno R, Migliorati K, Spena G 94:1-27. Ducati A, Fontanella M. Blood-tissue analysis 18. Kondo T Molecular mechanisms involved of Tp53 polymorphisms and survival of patients with glioma. J Neurosurg Sci 2018 in gliomagenesis. Brain Tumor Pathol 2017, 34(1):1-7 9. Egan KM, Nabors LB, Olson JJ, Monteiro 19Vivanco l, Robins HI, Rohle D, Campos AN, Browning JE, Madden MH, Thompson RC. Rare TP53 genetic variant associated C, Grommes C, Nghiemphu PL, Kubek s Oldrini B. Chheda MG. Yannuzzin. et al with glioma risk and outcome. J Med Genet 2012,49(7):420-421 Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR 10. Zhang X, Tian Q, Wang L, Liu Y, Li B kinase inhibitors. Cancer Discovery 2012 Liang Z, Gao P, Zheng K, Zhao B, Lu H 2(5):458-471 Radiomics Strategy for Molecular Subtype 20. Yuan Y, Qi C, Maling G, Xiang W, Yanhui L, Stratification of lower-Grade glioma Detecting IDH and TP53 Mutations Based Ruofei L, Yunhe M, Jiewen L, Qing M. TERT mutation in glioma: Frequency, prognosis on Multimodal MRI. J Magnetic Resonance and risk. J Clin Neurosci 2016. 26: 57-62 Imaging 2018 1. Sarma PP dutta d, mirza z. saikia KK 21. Zhang Z, Chan AK, Ding X, Li Y, Zhang R, Baishya BK. Point mutations in the DNA Chen L, Liu Y, Wang Y, Xiong J, Ng HK et al. Glioma groups classified by IDH and binding domain of p53 contribute to TERT promoter mutations remain stable glioma progression and poor prognosis Molekuliarnaia Biologia 2017, 51(2 ): 334-341 among primary and recurrent gliomas Neuro-Oncol2017,19(7):1008-1010 12. Byeon SJ, Myung JK, Kim SH, Kim SK, Phi 22 Vuong HG, Altibi AMA, Duong UNP JH, Park SH. Distinct genetic alterations HTT Pham TQ. Chan AK, Park CK. FI in pediatric glioblastomas. Childs Nervous KM, Hassell L. TERT promoter mutation System2012,28(7):1025-1032 and its interaction with idh mutations in 13. Cheng Y, Ng HK, zhang SF, Ding M, Pang glioma: Combined TERT promoter and IDH MRF2018;2(1)2;Do:10.12208imrf20180002 收稿日期20180826出刊日期201 8-09-10杨海燕 et al. 神经胶质瘤多组学研究进展 IMRF 2018; 2:(1)2; DOI:10.12208/j.imrf.20180002 13 收稿日期 2018-08-26 出刊日期 2018-09-10 4．Yung WK. From GWAS risk foci to glioma molecular subclass. Neuro-oncology 2013, 15(5): 513-514. 5．Rood BR, MacDonald TJ. Pediatric high￾grade glioma: molecular genetic clues for innovative therapeutic approaches. J Neuro￾oncol 2005, 75(3): 267-272. 6．Isolan GR, Ribas Filho JM, Isolan PM, Giovanini A, Malafaia O, Dini LI, Kummer A, Jr., Negrao AW. Astrocytic neoplasms and correlation with mutate p53 and Ki- 67 proteins. Arquivos de Neuro-psiquiatria 2005, 63(4): 997-1004. 7．Wang YY, Zhang T, Li SW, Qian TY, Fan X, Peng XX, Ma J, Wang L, Jiang T. Mapping p53 mutations in low-grade glioma: a voxel-based neuroimaging analysis. Am J Neuroradiol 2015, 36(1): 70-76. 8．Panciani PP, Giordana MT, Gallone S, Muratori A, Rotunno R, Migliorati K, Spena G, Ducati A, Fontanella M. Blood-tissue analysis of TP53 polymorphisms and survival of patients with glioma. J Neurosurg Sci 2018. 9．Egan KM, Nabors LB, Olson JJ, Monteiro AN, Browning JE, Madden MH, Thompson RC. Rare TP53 genetic variant associated with glioma risk and outcome. J Med Genet 2012, 49(7): 420-421. 10.Zhang X, Tian Q, Wang L, Liu Y, Li B, Liang Z, Gao P, Zheng K, Zhao B, Lu H. Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI. J Magnetic Resonance Imaging 2018. 11.Sarma PP, Dutta D, Mirza Z, Saikia KK, Baishya BK. Point mutations in the DNA binding domain of p53 contribute to glioma progression and poor prognosis. Molekuliarnaia Biologiia 2017, 51(2): 334-341. 12.Byeon SJ, Myung JK, Kim SH, Kim SK, Phi JH, Park SH. Distinct genetic alterations in pediatric glioblastomas. Child's Nervous System 2012, 28(7): 1025-1032. 13.Cheng Y, Ng HK, Zhang SF, Ding M, Pang JC, Zheng J, Poon WS. Genetic alterations in pediatric high-grade astrocytomas. Human Pathol 1999, 30(11): 1284-1290. 14.Xiao WZ, Han DH, Wang F, Wang YQ, Zhu YH, Wu YF, Liu NT, Sun JY. Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis. Tumour Biol 2014, 35(7): 6687-6693. 15.Han F, Hu R, Yang H, Liu J, Sui J, Xiang X, Wang F, Chu L, Song S. PTEN gene mutations correlate to poor prognosis in glioma patients: a meta-analysis. Oncotargets Ther 2016, 9: 3485-3492. 16.Preusser M, Haberler C, Hainfellner JA. Malignant glioma: neuropathology and neurobiology. Wiener Medizinische Wochenschrift 2006, 156(11-12): 332-337. 17.Hulleman E, Helin K. Molecular mechanisms in gliomagenesis. Adv Cancer Res 2005, 94: 1-27. 18.Kondo T. Molecular mechanisms involved in gliomagenesis. Brain Tumor Pathol 2017, 34(1): 1-7. 19.Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discovery 2012, 2(5): 458-471. 20.Yuan Y, Qi C, Maling G, Xiang W, Yanhui L, Ruofei L, Yunhe M, Jiewen L, Qing M. TERT mutation in glioma: Frequency, prognosis and risk. J Clin Neurosci 2016, 26: 57-62. 21.Zhang Z, Chan AK, Ding X, Li Y, Zhang R, Chen L, Liu Y, Wang Y, Xiong J, Ng HK, et al. Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas. Neuro-Oncol 2017, 19(7): 1008-1010. 22.Vuong HG, Altibi AMA, Duong UNP, Ngo HTT, Pham TQ, Chan AK, Park CK, Fung KM, Hassell L. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH